CNM-Au8 Therapeutic Potential - Clene is pioneering catalytic nanotherapeutics to treat neurodegenerative diseases like ALS, Parkinson's, and MS[13] - CNM-Au8 is a nanocrystal suspension administered orally, targeting energy metabolism and oxidative stress, and can penetrate the blood-brain barrier[27] - CNM-Au8 contains >100 trillion nanocrystals per 60 mL dose (at 30 mg)[24] - Over 800 participant-years of exposure to CNM-Au8 with predominantly mild-to-moderate TEAEs and no related SAEs across all clinical programs[36] ALS Clinical Trial Outcomes - In the HEALEY ALS Platform Trial, CNM-Au8 30 mg showed a 94% risk reduction in time to death or PAV during the double-blind period[41] - During the OLE to Month 12 of the HEALEY ALS Platform Trial, CNM-Au8 30 mg showed a 78% risk reduction in time to death or PAV[46] and a 62% risk reduction in time to death[48] - A 71% risk reduction in delayed time to clinical worsening was observed in two independent Phase 2 trials[50] - Participants with NfL decline at Week 24 in the HEALEY ALS Platform Trial showed a 91% risk reduction in time to death or PAV[92] MS Clinical Trial Outcomes - In MS patients on DMTs, CNM-Au8 demonstrated significantly improved vision as measured by Change in Low Contrast Letter Acuity (LCLA)[124] - CNM-Au8 demonstrated global neurological improvement in stable MS patients on DMTs[123] Financial Status - As of March 31, 2025, Clene Inc had $9.8 million in cash and equivalents on hand (unaudited)[178]

长江证券年内收到第二份罚单。 6月30日，湖北证监局对长江证券出具警示函，指出该公司在证券投资顾问业务推广及客户回访环节存在记录留 存不完整的问题，反映出其证券投资顾问业务的合规管理不到位。 在股权变更推进的同时，长江证券主要管理干部也同步进行调整。2024年7月，刘正斌正式出任长江证券党委书 记。 年内长江证券新任董事长到位。今年4月3日，长江证券发布《长江证券股份有限公司第十届董事会第十七次会议 决议公告》，于当日召开第十届董事会第十七次会议中选举刘正斌为公司第十届董事会董事长。 履历显示，刘正斌曾任湖北省促进中部地区崛起工作办公室副主任（正处级），湖北省发改委国民经济综合处处 长、资源节约和环境保护处处长、综合交通处处长，湖北省铁路建设领导小组办公室主任（副厅长级），湖北省发改 委党组成员、副主任。 业绩表现上，2024年，长江证券实现总营收67.97亿元，同比下滑1.44%；实现归母净利润18.39亿元，同比增长 18.81%。截至2024年末，公司总资产1717.89亿元。 早在今年3月底，证监会对长江证券采取责令改正的行政监管措施，主要原因是其在投行业务执业过程中，存在 质控现场核查制度执行不到位 ...

Key Takeaways RTX unit Raytheon won a $49.8M contract to support SM-6 Tactical All-Up Rounds full-rate production. The SM-6 defends against multiple threats and has over 500 units delivered to the U.S. Navy. Contract work will be completed by April 2029, mainly in Tucson, AZ, and East Camden, AR.RTX Corporation’s (RTX) unit, Raytheon, recently secured a $49.8 million modification contract encompassing the manufacturing, assembly, testing and delivery of Standard Missile-6 (SM-6) Tactical All-Up Rounds to ...

7月1日晚间，上纬新材发布公告称，公司控股股东正在筹划重大事项，可能导致公司控制权变更。 | 序号 | 股东名称 | 持股数量(股) | 占总股本比例(%) | 期未参考市值(亿元) | | --- | --- | --- | --- | --- | | 1 ? | 上纬企业股份有限公司 | 258,229,392 | 64.02 | 19.50 | | 2 | Strategic Capital Holding Limited | 61,287,730 | 15.19 | 4.63 | | 3 | 金风投资控股有限公司 | 21,800,883 | 5.40 | 1.65 | | 4 | 何明坤 | 2,046,254 | 0.51 | 0.15 | | 5 | 沈茜 | 1,300,000 | 0.32 | 0.10 | | 6 | 徐玉莲 | 1.180.000 | 0.29 | 0.09 | | 7 | ② 緯港投資有限公司 | 995,763 | 0.25 | 0.08 | | 8 | 须绍宗 | 862,000 | 0.21 | 0.07 | | 9 | 曹志高 | 858,000 | 0.21 ...

Key Takeaways Palomar raised its 2025 adjusted net income guidance to $186-$200 million. Premium growth is supported by rising policy volume, strong retention and new partnerships. PLMR maintains a debt-free balance sheet and strong capital position.Shares of Palomar Holdings, Inc. (PLMR) have gained 85.4% in the past year, outperforming its industry, the Finance sector and the Zacks S&P 500 composite’s growth of 19.5%, 20.9% and 12.5%, respectively. The insurer has a market capitalization of $4.12 billio ...

Key Takeaways AMT benefits from 5G demand and its portfolio of 149,000 global communication sites. Long-term tower leases and divestment of risky assets support stable recurring revenues. Plans to invest more than $600M in data centers in 2025 to tap into the booming AI and cloud market.American Tower (AMT) is well-positioned to benefit from increased investment by wireless carriers in 5G networks. The long-term leases with its tenants assure stable cash flows. Prudent capital-allocation strategy and stro ...

北京时间7月1日晚，美股三大指数低开，截至发稿，道指微涨，纳指、标普微跌。 | 道琼斯 | 纳斯达克 | 标普500 | | --- | --- | --- | | 44367.30 | 20277.16 | 6198.72 | | +272.53 +0.62% | -92.57 -0.45% | -6.23 -0.10% | | 中国金龙指数 | 纳指100期货 | 标普500期货 | | 7351.43 | 22840.50 | 6252.00 | | +11.95 +0.16% | -52.75 -0.23% | -1.75 -0.03% | 鲍威尔回应7月降息 鲍威尔重申，关税影响预计将在未来几个月的通胀数据中显现，但他也承认不确定因素依然存在。"我 们预期夏季期间将出现更高的通胀水平。当前明智的做法是等待并获取更多信息。" 但鲍威尔补充道，"关税影响有可能高于或低于预期，到来的时间可能早于或晚于预期"，政策制定者对 这些有心理准备。 鲍威尔表示，绝大多数美联储委员预计今年晚些时候会降息。 当被问及7月降息是否为时过早时，鲍威尔表示："我真的不能说。这将取决于数据，我们将逐次会议进 行讨论。" 鲍威尔 ...

Core Insights - Bespoke Extracts, Inc. has successfully rebranded as The Joint Company (TJC) and launched new products, Doobskis and Dutch Blunts, which are gaining traction in Colorado's cannabis market [3][5] - Despite an 8.8% contraction in Colorado's regulated cannabis market, the company achieved year-over-year revenue growth [5] - The company is focused on expanding its market share and optimizing operations for sustainable growth [8] Financial Highlights for Q1 2025 - Revenue increased to $263,159, up 1.0% from $260,428 in Q1 2024, driven by strong sales of branded pre-rolled joints [7] - Gross profit rose to $110,779 from $102,581 in Q1 2024, supported by improved production efficiencies [7] - Operating expenses decreased to $356,117 from $405,384 in Q1 2024, reflecting lower stock-based compensation and reduced salaries [7] - Net loss decreased to $260,521 from $314,118 in Q1 2024 [7] Operational Highlights - Daily pre-roll production increased by 32% compared to Q1 2024, enhancing TJC's competitive processing capabilities [8] - The company achieved cost efficiencies in raw materials, packaging, and labor, boosting gross margins despite increased marketing costs [8] - Management is exploring expansion into other state-regulated cannabis markets, leveraging successful operations in Colorado [8] Fiscal Q2 2025 Outlook - Projected revenue for Q2 2025 is expected to exceed $385,000, compared to $278,163 in Q2 2024, driven by strong demand for new product lines [11] - Continued improvements in manufacturing processes are anticipated to support higher production volumes and consistent product quality [11] - Enhanced production efficiencies and cost management are projected to drive higher gross margins [11]

合成生物学技术是实现其工业化的有效途径。然而， 该类物质发酵后期随着产物积累体系呈现高粘 非牛顿流体特征，高分子链出现缠结凝胶化并包裹菌体细胞，导致"作茧自缚"，溶氧容易出现聚并 现象逸出罐体，难以跨越气液和胞外聚合物等多重屏障被菌体利用，严重抑制氧气和营养物质的代谢 利用，传氧传质效率低下 成为除菌种遗传物质外影响产量提升的最大瓶颈，生物合成水平难以提 升，这也是生物大分子产业化面临的共性技术难题。 【 SynBioCon 】 获 悉 ， 近 日 ， 南 京 工 业 大 学 徐 虹 教 授 、 王 瑞 教 授 团 队 在 《 Chemical Engineering Journal 》 发 表 了 题 为 "A novel bioreactor developed for the intensification of high-viscosity aerobic fermentation processes" 的研究论文，该工作针对生物大分子活性物质发 酵过程特有的 "三高"特征（高粘稠、高需氧、高能耗） ，通过激光烧结3D打印技术和计算流体力学原 理设计开发了 新型微气泡生物反应器平台 ，耦合菌株生理信号 ...

全球政策进展 | 英国 "人类基因组合成工程"一直是科学潜力与伦理困境交织的热点话题。科学家希望通过化学方法合成完整的人类基因组，从而将生命科学从"解读"与"修 补"推进到真正意义上的"书写"。然而，由于涉及重大的伦理争议，该领域在过去几十年一直未被广泛推进。 【SynBioCon】 获 悉， 6 月 30 日，英国《卫报》披露一项重大科学计划： 由牛津大学杰森・钦教授领导，剑桥大学、帝国理工学院 等 7 所高校 参 与的 " 合成人类基因组计划 "（SynHG）已正式启动。 作为全球首个同类研究项目，其首期获得威康信托基金会 1000 万英镑资助 ，目标是通过化学合成手段构建完整人类基因组，相关成果于《自然》子刊同 步发表。 SynHG 的目标是开发基础性工具和方法 ，为未来更多研究者提供能力支持。这个研究进程本身将极大可能催生合成生物工程领域的新技术，即便在完整 人类基因组合成 实现 之前，也可能带来关于细胞如何使用其基因组的新发现。 未来五年内，SynHG 项目将搭建完成基础技术框架。 在未来的 5-10 年，SynHG 团队的目标则是人工合成一条完整的人类染色体 。这个项目雄心勃 勃且困难重重，需攻克 ...